<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885598</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-259</org_study_id>
    <nct_id>NCT01885598</nct_id>
  </id_info>
  <brief_title>Eliquis Regulatory Post Marketing Surveillance</brief_title>
  <official_title>Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the
      clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the
      safety and effectiveness information about Eliquis in general practice
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Occurrence of stroke, systemic embolism and death</measure>
    <time_frame>At each visit (3, 6, 12 and 24 months)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>NONVALVULAR ATRIAL FIBRILLATION</condition>
  <arm_group>
    <arm_group_label>Nonvalvular Atrial Fibrillation patients with risk of Stroke</arm_group_label>
    <description>Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Nonvalvular Atrial Fibrillation patients with risk of Stroke</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic physicians should enroll all adult patients who are diagnosed with
        nonvalvular atrial fibrillation and who need anticoagulation therapy for risk reduction of
        stroke and systemic embolism and who are receiving Eliquis 5 mg or 2.5 mg for the first
        time
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥19 years of age

          -  Adult patients who are diagnosed with nonvalvular atrial fibrillation and are
             initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic
             embolism

          -  Patients with evidence of a personally signed and dated informed consent document
             indicating that the patient (or a legally acceptable representative) has been
             informed of all pertinent aspects of the study

        Exclusion Criteria:

          -  Receiving Eliquis treatment for an indication that is not approved in Korea

          -  Contraindicated for the use of Eliquis as described in the Korean label
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 15, 2013</lastchanged_date>
  <firstreceived_date>June 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
